Coordinated and spatial upregulation of Arc in striatonigral neurons correlates with L-Dopa-induced behavioral sensitization in dyskinetic rats

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 11, 2005, Pages 936-947

  Sgambato Faure, Véronique ^a,c   Buggia, Virginie ^a   Gilbert, François ^b   Lévesque, Daniel ^b   Benabid, Alim Louis ^a   Berger, François ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b LAVAL UNIVERSITY   (Canada)

^c INSERM   (France)

Author keywords

Arc; Dynorphin; Dyskinesia; Homer 1a; L Dopa; Locomotor sensitization; Nur77

Indexed keywords

DYNORPHIN; LEVODOPA; TRANSCRIPTION FACTOR FOSB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CYTOSKELETON; DYSKINESIA; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MOLECULAR DYNAMICS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; UPREGULATION;

EID: 27944469585     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000186922.42592.b7     Document Type: Article

References (88)

1. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236-39
2. Agid Y. Parkinson's disease: Some physiopathological aspects and clinical practice. Rev Prat 1989;39:641-46
3. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. The basal ganglia and disorders of movement: Pathophysiological mechanisms. News Physiol Sci 2002;17:51-55
4. Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson's disease: Importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62:S17-30
5. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs 2004;5:720-26
6. Birkmayer W, Hornykiewicz O. Der L-Dioxyphenylalanin (4DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wschr 1961;73:787-88
7. Barbeau A. L-Dopa therapy in Parkinsonvs disease: A critical review of nine years experience. Can Med Assoc J 1969;101:791-800
8. Krack P, Pollak P, Limousin P, et al. From off-period dystonia to peak-dose chorea: The clinical spectrum of varying subthalamic nucleus activity. Brain 1999;122:1133-46
9. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2001;8:101-8
10. Rascol O, Fabre N. Dyskinesia: L-Dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001;24:313-23
11. Defebvre L. Motor complications in dopa treatment of Parkinson disease: Clinical description and evaluation. Thérapie 2004;59:93-6
12. Di Monte DA, McCormack A, Petzinger G, et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-66
13. Baas H, Fuchs G, Gemende I, et al. Which factors influence therapeutic decisions in Parkinson's disease? J Neurol 2002;249:49-52
14. Winkler C, Kirik D, Bjorklund A, et al. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002;10:165-86
15. Paille V, Brachet P, Damier P. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport 2004;15:561-64
16. Jenner P. Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62:S47-55
17. Calon F, Tahar AH, Blanchet PJ, et al. Dopamine-receptor stimulation: Biobehavioral and biochemical consequences. Trends Neurosci 2000;23:S92-S100
18. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: A new hypothesis. Trends Neurosci 2000;23:S71-77
19. Bevan MD, Magill PJ, Terman D, et al. Move to the rhythm: Oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci 2002;25:525-31
20. Hutchison WD, Dostrovsky JO, Walters JR, et al. Neuronal oscillations in the basal ganglia and movement disorders: Evidence from whole animal and human recordings. J Neurosci 2004;24:9240-43
21. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501-6
22. Chase TN. Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:S17-25
23. Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 2004;10:305-13
24. Matsumoto RR, Brinsfield KH, Patrick RL, et al. Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists. J Pharmacol Exp Ther 1988;246:196-203
25. Carey RJ. Naloxone reverses L-Dopa induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci 1991;48:1303-8
26. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:149-58
27. Marin C, Engber TM, Chaudhuri P, et al. Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors. Psychopharmacology 1996;123:215-21
28. Newman DD, Rajakumar N, Flumerfelt BA, et al. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. Neuroreport 1997;8:669-72
29. Henry B, Fox SH, Crossman AR, et al. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001;171:139-46
30. Calabresi P, Giacomini P, Centonze D, et al. Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity? Ann Neurol 2000;47:60-68
31. Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000;23:86-91
32. Link W, Konietzko U, Kauselmann G et al. Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci U S A 1995;92:5734-38
33. Lyford GL, Yamagata K, Kaufmann WE, et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 1995;14:433-45
34. Steward O, Wallace CS, Lyford GL, et al. Synaptic activation causes the mRNA for the IEG Arc to localize selectively near activated postsynaptic sites on dendrites. Neuron 1998;21:741-51
35. Steward O, Worley P. Local synthesis of proteins at synaptic sites on dendrites: Role in synaptic plasticity and memory consolidation? Neurobiol Learn Mem 2002;78:508-27
36. Guzowski JF, Lyford GL, Stevenson GD, et al. Inhibition of activity-dependent Arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci 2000;20:3993-4001
37. Plath N, Ohana O, Dammermann B, et al. Aberrant LTP in arg3.1/ARC knockout animals. Soc Neurosci Abstr 2001;27:1598
38. Ying SW, Futter M, Rosenblum K, et al. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: Requirement for ERK activation coupled to CREB and up-regulation of Arc synthesis. J Neurosci 2002;22:1532-40
39. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1986
40. Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with 1-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999;6:461-74
41. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-2706
42. Beaudry G, Langlois MC, Weppe I, et al. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J Neurochem 2000;75:1694-1702
43. Sgambato V, Pages C, Rogard M, et al. Extracellular signal-regulated kinase (ERK) controls immediate early gene induction on corticostriatal stimulation. J Neurosci 1998;18:8814-25
44. Nestler EJ, Kelz MB, Chen J. ΔFosB: A molecular mediator of long-term neural and behavioral plasticity. Brain Res 1999;835:10-17
45. Thomas U. Modulation of synaptic signalling complexes by homer proteins. J Neurochem 2002;81:407-13
46. Fagni L, Worley PF, Ango F. Homer as both a scaffold and transduction molecule. Sci STKE 2002;137:RE8
47. Fagni L, Ango F, Perroy J, et al. Identification and functional roles of metabotropic glutamate receptor-interacting proteins. Semin Cell Dev Biol 2004;15:289-98
48. St-Hilaire M, Landry E, Levesque D, et al. Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats. Neurobiol Dis 2003;14:98-109
49. Hill RG. The status of naloxone in the identification of pain control mechanisms operated by endogenous opioids. Neurosci Lett 1981;21:217-22
50. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and norbinaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 1987;40:1287-92
51. Piercey MF, Lahti RA, Schroeder LA, et al. U-50,488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse. Life Sci 1982;31:1197-1200
52. Fosnaugh JS, Bhat RV, Yamagata K, et al. Activation of Arc, a putative 'effector' immediate early gene, by cocaine in rat brain. J Neurochem 1995;64:2377-80
53. Tan A, Moratalla R, Lyford GL, et al. The activity-regulated cytoskeletal-associated protein Arc is expressed in different striosome-matrix patterns following exposure to amphetamine and cocaine. J Neurochem 2000;74:2074-78
54. Konradi C, Westin JE, Carta M, et al. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 2004;17:219-36
55. Freeman WM, Brebner K, Lynch WJ, et al. Changes in rat frontal cortex gene expression following chronic cocaine. Brain Res Mol Brain Res 2002;104:11-20
56. Marie-Claire C, Courtin C, Roques BP, et al. Cytoskeletal genes regulation by chronic morphine treatment in rat striatum. Neuropsychopharmacology 2004;29:2208-15
57. Fujimoto T, Tanaka H, Kumamaru E, et al. Arc interacts with microtubules/microtubule-associated protein 2 and attenuates microtubule-associated protein 2 immunoreactivity in the dendrites. J Neurosci Res 2004;76:51-63
58. Donai H, Sugiura H, Ara D, et al. Interaction of Arc with CaM kinase II and stimulation of neurite extension by Arc in neuroblastoma cells expressing CaM kinase II. Neurosci Res 2003;47:399-408
59. Steward O, Worley PF. Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 2001;30:227-40
60. Martin KC. Arc mRNA dynamics: Return to sender - the NMDA receptor provides the targeting address for Arc mRNA. Trends Neurosci 2001;24:621-23
61. Robelet S, Melon C, Guillet B, et al. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 2004;20:1255-66
62. Sheng M, Kim E. The Shank family of scaffold proteins. J Cell Sci 2000;113:1851-56
63. Brakeman PR, Lanahan AA, O'Brian R, et al. Homer: A protein that selectively binds to metabotropic glutamate receptors. Nature 1997;386:284-88
64. Berke JD, Paletzki RF, Aronson GJ, et al. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 1998;18:5301-10
65. Bottai D, Guzowski JF, Schwarz MK, et al. Synaptic activity-induced conversation of intronic to exonic sequence in Homer 1 immediate early gene expression. J Neurosci 2002;22:167-75
66. Xiao B, Tu JC, Petralia RS, et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron 1998;21:707-16
67. Tu JC, Xiao B, Yuan JP, et al. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 1998;21:717-26
68. Ango F, Prézeau L, Muller T, et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 2001;411:962-65
69. Ango F, Robbe D, Tu JC, et al. Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons. Mol Cell Neurosci 2002;20:323-29
70. Bergson C, Levenson R, Goldman-Rakic PS, et al. Dopamine receptor-interacting proteins: The Ca(2+) connection in dopamine signaling. Trends Pharmacol Sci 2003;24:486-92
71. Dickey CA, Loring JF, Montgomery J, et al. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 2003;23:5219-26
72. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982;215:413-15
73. Vincent S, Hokfelt T, Christensson I, et al. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur J Pharmacol 1982;85:251-52
74. Gerfen CR, Young WS. 3rd Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res 1988;460:161-67
75. Meshul CK, McGinty JF. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 2000;96:91-99
76. Abou-Khalil B, Young AB, Penney JB. Evidence for the presynaptic localization of opiate binding sites on striatal efferent fibers. Brain Res 1984;323:21-29
77. Samadi P, Gregoire L, Bedard PJ. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: Interaction between dopamine and opioid systems. Neuropharmacology 2003;45:954-63
78. Johansson PA, Andersson M, Andersson KE, et al. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of 1-DOPA-induced dyskinesia. Neurobiol Dis 2001;8:220-39
79. Morris BJ, Herz A. Control of opiate receptor number in vivo: Simultaneous kappa-receptor down-regulation and mu-receptor upregulation following chronic agonist/antagonist treatment. Neuroscience 1989;29:433-42
80. Moore RY, Bhatnagar RK, Heller A. Anatomical and chemical studies of a nigro-neostriatal projection in the cat. Brain Res 1971;30:119-35
81. Doucet G, Descarries L, Garcia S. Quantification of the dopamine innervation in adult rat neostriatum. Neuroscience 1986;19:427-45
82. Parent A, Mackey A, De Bellefeuille L. The subcortical afferents to caudate nucleus and putamen in primate: A fluorescence retrograde double labeling study. Neuroscience 1983;10:1137-50
83. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci 1990;13:254-58
84. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 1990;13:259-65
85. Smith Y, Raju DV, Pare JF, et al. The thalamostriatal system: A highly specific network of the basal ganglia circuitry. Trends Neurosci 2004;27:520-27
86. McGeorge AJ, Faull RL. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 1989;29:503-37
87. Berendse HW, Galis-de Graaf Y, Groenewegen HJ. Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J Comp Neurol 1992;316:314-47
88. Van der Kooy D. The organization of the thalamic, nigral and raphe cells projecting to the medial vs lateral caudate-putamen in rat. A fluorescent retrograde double labeling study. Brain Res 1979;169:381-87